原发性硬化性胆管炎的治疗进展

鲍正华; 韩真

原发性硬化性胆管炎的治疗进展

鲍正华,
韩真

皖南医学院弋矶山医院消化内科

详细信息

中图分类号: R575.7
计量
- 文章访问数: 3275
- HTML全文浏览量: 9
- PDF下载量: 980
- 被引次数: 0
出版历程
- 出版日期: 2011-06-20

Progress in the treatment of primary sclerosing cholangitis

摘要

摘要: 原发性硬化性胆管炎(PSC)是一种原因不明的慢性胆汁淤积性自身免疫性肝病,其确切的发病机制尚未明确,可能与遗传、免疫、损伤等多种因素有关,诊断及治疗均较为困难。本文就原发性硬化性胆管炎的治疗作一综述,以期加深对该病的了解,为进一步的临床治疗提供依据。
- 胆管炎 /
- 硬化性
Abstract: Primary sclerosing cholangitis is a chronic autoimmune cholestatic liver disease with unclear etiology, which may refer to genetics, immunology and injury factors.It is very difficult to diagnose and treat.This article introduces the studies of the therapy of PSC to further understand the disease of PSC and provide new evidences for treating PSC.
- cholangitis /
- sclerosing

HTML全文

参考文献(26)

[1]胆汁淤积性肝病诊断治疗专家委员会.胆汁淤积性肝病诊断治疗专家共识[J].中华实验和临床感染病杂志 (电子版) , 2009, 3 (4) :60-61.

[2]Maggs JR, Chapman RW.An update on primary sclerosingcholangitis[J].Curr Opin Gastroenterol, 2008, 24 (3) :377-383.

[3]Beuers U.Drug insight:Mechanisms and sites of actionof ursodeoxycholic acid in cholestasis[J].Nat Clin PractGastroenterol Hepatol, 2006, 3 (6) :318-328.

[4]European Association for the Study of the Liver.ESAL ClinicalPractice Guidelines:management of cholestatic liver disease[J].J Hepatol, 2009, 51 (2) :237-267.

[5]Olsson R, Boberg KM, de Muckadell OS, et al.High-doseursodeoxycholic acid in primary sclerosing cholangitis:a 5-yearmulticenter, randomized, controlled study[J].Gastroenterology, 2005, 129 (5) :1464-1472.

[6]Rost D, Rudolph G, Kloeters-plachky P, et al.Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primarysclerosing cholangitis[J].Hepatology, 2004, 40 (3) :693-698.

[7]陆伦根, 田丽艳, 徐铭益, 等.欧洲肝病学会临床实践指南:胆汁淤积性肝病的治疗 (3) [J].肝脏, 2010, 15 (1) :44-48.

[8]Herszényi L, Farinati F, Miheller P, et al.Chemoprevention ofcolorectal cancer:feasibility in everyday practice[J].Eur JCancer Prev, 2008, 17 (6) :502-514.

[9]Rudolph G, Kloeters-Plachky P, Rost D, et al.The incidenceof cholangiocarcinoma in primary sclerosing cholangitisafter long-time treatment with ursodeoxycholic acid[J].Eur JGastroenterol Hepatol, 2007, 19 (6) :487-491.

[10]Chapman R, Fevery J, Kalloo A, et al.Diagnosis and management of primary sclerosing cholangitis[J].Hepatology, 2010, 51 (2) :660-678.

[11]Mato JM, Lu SC.Role of S-adenosyl-L-methionine in liverhealth and injury[J].Hepatology, 2007, 45 (5) :1306-1312.

[12]Lu SC, Mato JM.S-Adenosylmethionine in cell growth, apoptosis and liver cancer[J].J Gastroenterol Hepatol, 2008, 23 (Suppl 1) :S73-77.

[13]Chen W, Gluud C.Glucocorticosteroids for primary sclerosingcholangitis[J].Cochrane Patabase Syst Rev, 2010, 20 (1) :CD004036.

[14]Arulprakash S, Sasi AD, Bala MR, et al.Overlap syndrome:autoimmune hepatitis with primary biliary cirrhosis[J].J AssocPhysicians India, 2010, 58:455-456.

[15]Sandborn WJ, Wiesner RH, Tremaine WJ, et al.Ulcerative colitisdisease activity following treatment of associated primarysclerosing cholangitis with cyclosporin[J].Gut, 1993, 34 (2) :242-246.

[16]邱德凯, 马雄.自身免疫性肝病基础与临床[M].上海:上海科学技术出版社, 2006:281-287.

[17]Van Thiel DH, Carroll P, Abu-Elmagd K, et al.Tacrolimus (FK506) , a treatment for prima-ry sclerosing cholangitis:results ofan open-label preliminary trial[J].Am J Gastroenterol, 1995, 90 (3) :455-459.

[18]Talwalkar JA, Gossard AA, Keach JC, et al.Tacrolimus for thetreatment of primary sclerosing cholangitis[J].Liver Int, 2007, 27 (4) :451-453.

[19]Olsson R, Bmome U, Danielsson A, et al.Colchicine treatmentof primary sclemsing eholang-itis[J].Gastroenterology, 1995, 108 (4) :1199-1203.

[20]Farkkila M, Karvonen AL, Nurmi H, et al.Metronidazole andursodeoxycholic acid for prim-ary sclerosing cholangitis:arandomized placebo-controlled trial[J].Hepatology, 2004, 40 (6) :1379-1386.

[21]Gluck M, Cantone NR.Brandabur JJ, et al.A twenty-yearexperience with endoscopic therapy for symptomatic primarysclerosing cholangitis[J].J Clin Gastroenterol, 2008, 42 (9) :1032-1039.

[22]Aljiffry M, Renfrew PD, Walsh MJ, et al.Analytical review ofdiagnosis and treatment strategies for dominant bile ductstrictures in patients with primary sclerosing.cholangitis[J].HPB (Oxford) , 2011, 13 (2) :79-90.

[23]Wagner S, Gebel M, Meier P, et al.Endoscopic managementof biliary tract strictures in primary sclerosing cholangitis[J].Endoscopy, 1996, 28 (7) :546-551.

[24]Pawlik TM, Olbrecht VA, Pitt HA, et al.Primary sclerosingcholangitis:role of extrahepatic biliary resection[J].J Am CollSurg, 2008, 206 (5) :822-830.

[25]Alabraba E, Nightingale P, Gunson B, et al.A re-evaluation of therisk factors for the recurrence of primary sclerosing cholangitis inliver allografts[J].Liver Transpl, 2009, 15 (3) :330-340.

[26]Kingham JG, Kochar N, Gravenor MB.Incidence, clinicalpatterns, and outcomes of primary sclerosing cholangitis inSouth Wales, United Kingdom[J].Gastroenterology, 2004, 126 (7) :1929-1930.

施引文献

资源附件(0)

访问统计